Forest Infasurf Marketing Awaits Resolution Of Abbott Patent Case
Executive Summary
Patent litigation with Abbott is complicating Forest's marketing plans for its lung surfactant Infasurf, which was approved July 1 for "the prevention and treatment of respiratory distress syndrome in neonates."